Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

NCT01300429 ·Status: COMPLETED

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

NCT04009317 ·Status: UNKNOWN ·Phase: PHASE3

A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer

NCT03155009 ·Status: COMPLETED ·Phase: PHASE2

Descriptive Observational Study ALK-2016-CPHG

NCT03718117 ·Status: COMPLETED

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

NCT01685138 ·Status: COMPLETED ·Phase: PHASE2

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

NCT02487316 ·Status: WITHDRAWN ·Phase: PHASE4

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

NCT02336451 ·Status: COMPLETED ·Phase: PHASE2

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

NCT02499614 ·Status: UNKNOWN ·Phase: PHASE2

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

NCT04056572 ·Status: UNKNOWN ·Phase: PHASE2

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

NCT02075840 ·Status: COMPLETED ·Phase: PHASE3

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

NCT01945021 ·Status: COMPLETED ·Phase: PHASE2

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

NCT02737501 ·Status: COMPLETED ·Phase: PHASE3

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT04632758 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

NCT03535740 ·Status: COMPLETED ·Phase: PHASE2

Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

NCT05792644 ·Status: COMPLETED ·Phase: NA

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

NCT04647110 ·Status: COMPLETED

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 ·Status: COMPLETED ·Phase: PHASE2

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

NCT05167500 ·Status: COMPLETED

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

NCT05014464 ·Status: RECRUITING ·Phase: PHASE2

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

NCT02034981 ·Status: COMPLETED ·Phase: PHASE2

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

NCT01597258 ·Status: COMPLETED

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02838420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

NCT03672643 ·Status: TERMINATED ·Phase: PHASE4

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

NCT02228421 ·Status: TERMINATED

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT06254599 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3